| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22050 |
| Drug | Trastuzumab deruxtecan |
| Brand | Enhertu® |
| Indication | As monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. |
| Assessment Process | |
| Rapid review commissioned | 11/07/2022 |
| Rapid review completed | 27/07/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of trastuzumab deruxtecan compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/08/2022 |
| Pre-submission consultation with Applicant | 25/10/2022 |
| Full submission received from Applicant | 09/03/2023 |
| Preliminary review sent to Applicant | 15/09/2023 |
| NCPE assessment re-commenced | 13/10/2023 |
| Factual accuracy sent to Applicant | 23/11/2023 |
| NCPE assessment re-commenced | 30/11/2023 |
| NCPE assessment completed | 12/12/2023 |
| NCPE assessment outcome | The NCPE recommends that trastuzumab deruxtecan (Enhertu®) be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
